Brief: Eiger BioPharmaceuticals Inc Announces An Oral Poster Presentation Of Phase 2 Study Results Of Avexitide In Congenital Hyperinsulinism
28/06/2021 14:13
June 28 (Reuters) - Eiger BioPharmaceuticals Inc EIGR.O :
* EIGER BIOPHARMACEUTICALS INC - ANNOUNCED AN ORAL POSTER
PRESENTATION OF PHASE 2 STUDY RESULTS OF AVEXITIDE IN CONGENITAL
HYPERINSULINISM (HI)
* EIGER BIOPHARMACEUTICALS - AVEXITIDE SIGNIFICANTLY REDUCED
GIR
WHEN EVALUATED ACROSS DOSE LEVELS (P=0.0087) WITH DOSE-DEPENDENT
IMPROVEMENTS OBSERVED
* EIGER BIOPHARMACEUTICALS - ADVERSE EVENTS WERE TYPICALLY
MILD IN
SEVERITY & TRANSIENT, & THERE WERE NO SERIOUS ADVERSE EVENTS IN
PHASE 2 AVEXITIDE STUDY
Source text for Eikon: ID:nPn3rWFVva
Further company coverage: EIGR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eiger Biopharmaceuticals
See all newsBrief: Eiger Biopharmaceuticals On Sept 5, Bankruptcy Court Entered Order Confirming Fifth Amended Joint Plan Of Liquidation Of Co & Its Debtor Affiliates
Amylyx to buy bankrupt Eiger's experimental drug to treat low blood sugar
Brief: Eiger Biopharmaceuticals And Amylyx Entered Into An Asset Purchase Agreement
Eiger BioPharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Eiger BioPharmaceuticals Inc expected to post a loss of $7.50 a share - Earnings Preview